Zhengye Biotechnology Holding (ZYBT) Accumulated Expenses (2023 - 2025)

Zhengye Biotechnology Holding (ZYBT) has reported Accumulated Expenses for 3 consecutive years, with $488257.4 the latest figure, recorded in Q4 2025.

• Quarterly Accumulated Expenses fell 37.56% year-over-year to $488257.4 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $488257.4 (down 37.56% YoY) and the FY2025 annual result came in at $495000.0, down 35.63% from the prior year.
• Accumulated Expenses slipped to $488257.4 in Q4 2025 per ZYBT's latest filing, from $529000.0 in the prior quarter.
• Over the last five years, Accumulated Expenses for ZYBT reached as high as $781974.7 in Q4 2024 and fell as low as $400273.5 in Q4 2023.
• A 3-year average of $549876.4 and a median of $508628.7 in 2025 frame the typical range for Accumulated Expenses.
• Annual changes were most pronounced in 2024 — Accumulated Expenses jumped 95.36% — and 2025, when it sank 37.56%.
• Year by year, Accumulated Expenses stood at $400273.5 in 2023, then soared by 95.36% to $781974.7 in 2024, then plunged by 37.56% to $488257.4 in 2025.
• According to Business Quant data, Accumulated Expenses over the past three periods registered $488257.4, $529000.0, and $781974.7 for Q4 2025, Q2 2025, and Q4 2024 respectively.